% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/data-documentation.R
\docType{data}
\name{ihc_molecular_comprehensive}
\alias{ihc_molecular_comprehensive}
\title{Enhanced IHC and Molecular Pathology Comprehensive Dataset}
\format{
A data frame with 400 rows and 50 variables:
\describe{
\item{Patient_ID}{Character. Unique patient identifier (MP0001-MP0400)}
\item{Age}{Numeric. Patient age in years (18-95)}
\item{Gender}{Character. Patient gender (Male/Female)}
\item{Institution}{Character. Institution type (Academic_Medical_Center/Community_Hospital/Cancer_Center/Regional_Hospital)}
\item{Pathologist_Experience}{Character. Pathologist experience level (Trainee/Junior/Senior/Expert)}

\item{Tumor_Type}{Character. Tumor classification including 16 major cancer types}
\item{T_Stage}{Character. Primary tumor stage (T1-T4)}
\item{N_Stage}{Character. Regional lymph node status (N0-N3)}
\item{M_Stage}{Character. Distant metastasis status (M0/M1)}
\item{Grade}{Numeric. Histologic grade (1-3)}

\item{EGFR_Mutation}{Character. EGFR mutation status (Positive/Negative)}
\item{KRAS_Mutation}{Character. KRAS mutation status (Positive/Negative)}
\item{BRAF_Mutation}{Character. BRAF mutation status (Positive/Negative)}
\item{PIK3CA_Mutation}{Character. PIK3CA mutation status (Positive/Negative)}
\item{BRCA1_Mutation}{Character. BRCA1 mutation status (Positive/Negative)}
\item{BRCA2_Mutation}{Character. BRCA2 mutation status (Positive/Negative)}

\item{ALK_Fusion}{Character. ALK fusion gene status (Positive/Negative)}
\item{ROS1_Fusion}{Character. ROS1 fusion gene status (Positive/Negative)}
\item{RET_Fusion}{Character. RET fusion gene status (Positive/Negative)}

\item{IDH1_Mutation}{Character. IDH1 mutation status (Positive/Negative)}
\item{MGMT_Methylation}{Character. MGMT promoter methylation status (Positive/Negative)}
\item{MSI_Status}{Character. Microsatellite instability status (MSI-High/MSI-Low/MSS)}
\item{Tumor_Mutational_Burden}{Numeric. Mutations per megabase (1-50)}

\item{HER2_IHC}{Character. HER2 immunohistochemistry score (0/1+/2+/3+)}
\item{HER2_FISH_Ratio}{Numeric. HER2 FISH ratio (performed on 2+ and 3+ cases)}
\item{HER2_FISH_Status}{Character. HER2 FISH amplification status (Amplified/Not_Amplified/Not_Performed)}
\item{PD_L1_TPS}{Numeric. PD-L1 Tumor Proportion Score (0-100\%)}
\item{PD_L1_CPS}{Numeric. PD-L1 Combined Positive Score (0-100)}
\item{PD_L1_IC}{Numeric. PD-L1 Immune Cell Score (0-100\%)}
\item{ER_Percentage}{Numeric. Estrogen receptor percentage (0-100\%, breast cases only)}
\item{PR_Percentage}{Numeric. Progesterone receptor percentage (0-100\%, breast cases only)}

\item{Ki67_Manual}{Numeric. Ki-67 proliferation index, manual count (1-90\%)}
\item{Ki67_AI_Assisted}{Numeric. Ki-67 proliferation index, AI-assisted count (0-100\%)}
\item{Ki67_Agreement}{Logical. Agreement between manual and AI scoring (within 5\%)}
\item{p53_Pattern}{Character. p53 staining pattern (Wild_type_pattern/Null_pattern/Overexpression)}
\item{CD8_Count_per_mm2}{Numeric. CD8+ T-cell count per mmÂ²}
\item{TIL_Percentage}{Numeric. Tumor-infiltrating lymphocytes percentage (0-80\%)}

\item{Platform_A_PD_L1}{Numeric. PD-L1 score on platform A (0-100\%)}
\item{Platform_B_PD_L1}{Numeric. PD-L1 score on platform B (0-100\%)}
\item{Platform_Agreement}{Logical. Multi-platform agreement (within 10\%)}

\item{Specimen_Adequacy}{Character. Specimen quality assessment (Adequate/Suboptimal/Inadequate)}
\item{Fixation_Time_Hours}{Numeric. Formalin fixation time in hours (2-24)}
\item{Molecular_TAT_Days}{Numeric. Molecular testing turnaround time in days (3+)}
\item{Diagnostic_Confidence}{Character. Pathologist confidence level (High/Moderate/Low)}
\item{EQA_Score}{Numeric. External quality assessment score (60-100)}

\item{Overall_Survival_Months}{Numeric. Overall survival in months (0.5-120)}
\item{Death_Event}{Numeric. Death event indicator (0/1)}
\item{PFS_Months}{Numeric. Progression-free survival in months}
\item{Progression_Event}{Numeric. Progression event indicator (0/1)}
\item{Treatment_Response}{Character. RECIST response (Complete_Response/Partial_Response/Stable_Disease/Progressive_Disease)}
}
}
\source{
Simulated comprehensive molecular pathology data
}
\usage{
ihc_molecular_comprehensive
}
\description{
A comprehensive dataset representing modern molecular pathology practice,
combining traditional immunohistochemistry with cutting-edge molecular diagnostics.
This dataset simulates real-world clinical laboratory scenarios including
multi-platform validation, digital pathology integration, and precision oncology applications.
Educational focus: Training pathologists and clinicians in integrated morphologic
and molecular diagnostics for personalized cancer care.
}
\examples{
data(ihc_molecular_comprehensive)
head(ihc_molecular_comprehensive)

# Modern molecular pathology workflow example
# 1. Analyze mutation frequencies by tumor type
table(ihc_molecular_comprehensive$Tumor_Type, ihc_molecular_comprehensive$EGFR_Mutation)

# 2. Evaluate digital pathology agreement
mean(ihc_molecular_comprehensive$Ki67_Agreement)

# 3. Multi-platform biomarker validation
cor(ihc_molecular_comprehensive$Platform_A_PD_L1, 
    ihc_molecular_comprehensive$Platform_B_PD_L1, use = "complete.obs")

# 4. Quality metrics assessment
table(ihc_molecular_comprehensive$Specimen_Adequacy)

# Educational applications:
# - Precision oncology decision-making
# - Digital pathology validation studies  
# - Multi-platform biomarker harmonization
# - Quality assurance in molecular diagnostics
}
\keyword{datasets}
